Clinical Trial

Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)

Study acronym: RAISE
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer (DTC). The traditional first line treatment for patients with advanced DTC after surgical resection is radioactive iodine (RAI) therapy. However, less than a quarter of patients with lung metastases will achieve a complete response to RAI therapy, and this therapy carries the risk of pulmonary fibrosis and an increasingly recognized risk of secondary malignancies.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2024-06-10; most recent amendment 2026-07-23.
Status change: Not Yet Recruiting → Recruiting 2024-11-11
Trial Details
NCT Number NCT06458036
Lead Sponsor Children's Hospital of Philadelphia
Collaborators: Eli Lilly and Company, United States Department of Defense
Conditions Differentiated Thyroid Cancer, Pediatric Cancer, Cancer, Cancer, Thyroid
Enrollment 13 participants
Start Date 2024-07-29
Primary Completion 2030-11-01 (estimated)
Study Completion 2031-11-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-24